

Value-Based Care Release Notes

December 12, 2025

Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS), and Enhancing Oncology Model (EOM), and Advanced Care Planning (ACP).

MIPS Quality Measures Dashboard

The MIPS Quality Measures Dashboard will be updated to reflect the following refinement(s):

Measure	Update	Practice Impact
MIPS 144: Pain Care Plan	Technical fix to ensure duplicate patients are not included in the denominator and numerator. Previously, there were G2 patients duplicated during the chart merger.	Practices will notice a decrease in Denominator and Numerator.
MIPS 450: Trastuzumab Received by Patients with AJCC Stage I (T1c), II, and III and HER2+ Breast Cancer Receiving Adjuvant Cancer	Technical fix to ensure HER2 status documentation is captured, and Denominator credit is attributed accurately.	Practices will notice an increase in Denominator and Numerator.
MIPS 451: RAS (KRAS & NRAS) Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-EGFR Monoclonal Antibody Therapy	Technical fix to ensure biomarker charting for KRAS/NRAS Mutation testing are accurately attributed to Numerator credit when documented.	Practices will notice an impact to their Numerator and performance rate.

EOM VBC Navigation Summary Dashboard

Starting Monday, December 15, 2025, VBC Navigation Summary Dashboard will display ePRO Enrollment data and Genetic Counseling Referral data.

ePRO Enrollment

ePRO Enrollment	ePRO Accepted Date	ePRO Declined Date	ePRO Ineligible Date
-----------------	--------------------	--------------------	----------------------

Genetic Counseling Referral

Genetic Counseling Referral	Genetic Counseling Referral Date
-----------------------------	----------------------------------

Advanced Care Planning Dashboards

Starting Monday, December 15, 2025, the Advance Care Planning Performance and Advance Care Planning Activities Dashboards will be updated with final data from Q2 2025.

Status of Dashboard Updates for 2025

CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. Ontada will continue to notify practices once measures have been updated based on the current 2025 requirements.

Measure Number	Description
MIPS Quality Measures Dashboard	
MIPS #001	Diabetes Hemoglobin A1c (HbA1cc) Poor Control (>9%) (Inverse Measure)
MIPS #047	Advance Care Plan
MIPS #130	Current Medications Documentation
MIPS #134 eCQM	Preventive Care Screening: Screening for Depression and Follow Up Plan
MIPS #134 CQM/Registry	Preventive Care Screening: Screening for Depression and Follow Up Plan
MIPS #143	Pain Intensity Quantified
MIPS #144	Pain Care Plan
MIPS #226	Tobacco Screening and Cessation
MIPS #236	Controlling High Blood Pressure
MIPS #238	Use of High-Risk Medications in Older Adults (Inverse Measure)
MIPS #374	Closing the Referral Loop
MIPS #450	Appropriate Treatment for Patients with Stage I (T1c) III Her2 Positive Breast Cancer
MIPS #451	RAS (KRAS & NRAS) Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-EGFR Monoclonal Antibody Therapy
MIPS #453	Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure)
MIPS #457	Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 Days
MIPS #462	Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy

Measure Number	Description
MIPS #487	Screening for Social Drivers of Health
PIMSH #1	Advance Care Planning in Metastatic Disease
PIMSH #4	Patient-Reported Pain Improvement
PIMSH #9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH #10	Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs
PIMSH #13	Proportion of Stage IV nsNSCLC Patients Tested for Actionable Biomarkers and Received Mutation-Targeted Therapy
PIMSH #15	Antiemetic Therapy for Low-and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH #16	Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center
PIMSH #17	Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy (Inverse Measure)
PIMSH #18	Resolution or Improvement of a Health-Related Social Need
EOM Performance Measures Dashboard	
EOM-4A	Pain Intensity Quantified
EOM-4B	Pain Care Plan
EOM-5	Preventive Care Screening: Screening for Depression and Follow Up Plan